Evaluating the Use of Anxiety Patient‐Reported Outcome Measures (PROMs) in Dementia Clinical Trials: A Systematic Review
Bewertung des Einsatzes von Anxiety Patient-Reported Outcome Measures (PROMs) in klinischen Demenzstudien: systematische Übersicht
Health Expectations · 2026-06 · 29 (3)
DOI: 10.1111/hex.70736 ↗Auf einen Blick
Die Übersicht zeigt: In Demenzstudien wurden validierte Angstmessungen häufig genutzt, PROMs aber nur in 44,4 %. Angst blieb meist proxy-berichtet.
Fragestellung
Wie werden validierte PROMs zur Erfassung von Angst in Demenzstudien eingesetzt, einschließlich Messinstrumenten, Methoden, demografischer Repräsentation und Evidenzlücken?
Methode
Systematische Übersicht nach PRISMA und Cochrane-Handbuch; RCTs von Januar 2015 bis Februar 2025; Suche in MEDLINE, Embase, PsycINFO, Cochrane Library und ClinicalTrials.gov.
Ergebnisse
29 Studien mit 5.697 Teilnehmenden. 93,1 % nutzten validierte Angstmessinstrumente, 44,4 % PROMs; am häufigsten die Hospital Anxiety and Depression Scale. 2.328 Datensätze gescreent.
Einschränkungen
Meiste Studien mit moderatem bis hohem Verzerrungsrisiko; Evidenz auf Länder mit hohem Einkommen beschränkt.
Schlussfolgerung der Autor:innen
Angstoutcomes in Demenzstudien sind weiterhin überwiegend proxy-berichtet. Es besteht Bedarf an demenzspezifischen, kulturell sensiblen Angst-PROMs.
Kernaussagen
- 44,4 % der Studien setzten PROMs ein, meist die Hospital Anxiety and Depression Scale
- Frauen und Personen weißer Ethnizität waren überrepräsentiert
- Keine Studie prüfte die Wirksamkeit nach Geschlecht und Ethnizität
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Systematische Übersicht in der Zeitschrift Health Expectations, online erschienen am 21.06.2026. Verfasst von Jason Domingo und 2 weiteren Autor:innen. Beteiligte Einrichtung: National Institute for Health and Care Research-Cambridge Clinical Research Facility, Cambridge University Hospitals NHS Foundation Trust, Cambridge,…. Hauptthemen laut MEDLINE: Anxiety, Dementia, Patient Reported Outcome Measures. Die Arbeit nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
Background
Anxiety is a common but underdetected or underdiagnosed symptom in dementia, affecting quality of life and care outcomes. Clinical trials are essential for informing effective management, yet the use of patient‐reported outcome measures (PROMs) in dementia trials remains unclear. This review examined how validated PROMs are used to assess anxiety in dementia trials, including measurement tools, methods, demographic representation and evidence gaps.
Methods
A systematic review was conducted following PRISMA and Cochrane Handbook guidance, with protocol registration on PROSPERO (CRD42025649920). Randomised controlled trials published between January 2015 and February 2025 were included if they assessed anxiety in mild to moderate dementia using validated PROMs within pharmacological or non‐pharmacological interventions. Searches were conducted across MEDLINE, Embase, PsycINFO, Cochrane Library and ClinicalTrials.gov, supplemented by citation tracking. Two reviewers independently undertook study selection, data extraction and risk of bias assessment. Due to heterogeneity, findings were narratively synthesised.
Results
Of 2328 records screened, 29 trials ( n = 5697) met inclusion criteria. While 93.1% used validated anxiety measurement tools, only 44.4% employed PROMs, most frequently the Hospital Anxiety and Depression Scale, mainly in non‐pharmacological trials. Women and individuals of White ethnicity were overrepresented, and no studies examined PROM effectiveness by sex and ethnicity. Most trials showed moderate to high risk of bias, and evidence was confined to high‐income countries.
Conclusions
Anxiety outcomes in dementia trials remain largely proxy‐reported. Existing anxiety PROMs are generic and unvalidated for dementia populations. There is a critical need for dementia‐specific, culturally sensitive anxiety PROMs, improved demographic reporting and integration of anxiety assessment within dementia core outcome sets. Patient or Public Contribution Feedback from research participants in dementia studies, who reported experiencing anxiety, motivated this systematic review. Patient and public involvement was examined across all included studies. The lack of validated dementia‐specific anxiety PROMs identified in this review highlights a broader gap in co‐produced outcome development within dementia research. These findings emphasise the need for meaningful involvement of people living with dementia and care partners in the development, validation and cultural adaptation of anxiety PROMs to ensure that trial outcomes are relevant, acceptable and representative.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- National Institute for Health and Care Research-Cambridge Clinical Research Facility, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
- Guy's and St Thomas' NHS Foundation Trust, London, UK.
- Faculty of Nursing, Midwifery & Palliative Care, King's College London, London, UK.
ORCID-Profile: Jason Domingo
Zitieren
APA
Domingo, J., Alves, A., & Sanders, J. (2026). Evaluating the Use of Anxiety Patient‐Reported Outcome Measures (PROMs) in Dementia Clinical Trials: A Systematic Review. Health Expectations, 29(3). https://doi.org/10.1111/hex.70736
Vancouver
Domingo J, Alves A, Sanders J. Evaluating the Use of Anxiety Patient‐Reported Outcome Measures (PROMs) in Dementia Clinical Trials: A Systematic Review. Health Expectations. 2026;29(3). doi:10.1111/hex.70736
BibTeX
@article{Domingo2026,
author = {Domingo, Jason and Alves, Ana and Sanders, Julie},
title = {Evaluating the Use of Anxiety Patient‐Reported Outcome Measures (PROMs) in Dementia Clinical Trials: A Systematic Review},
journal = {Health Expectations},
year = {2026},
volume = {29},
number = {3},
doi = {10.1111/hex.70736}
}
EUVIMED